Anatara Lifesciences Ltd (ASX:ANR)

14.0¢

right-arrow Created with Sketch. 0 (0%)
MCAP $9.984M
Last trade 13.18pm 07/12/2021 20mins delayed

Latest Announcements

06/12/2021ANRAnatara Lifesciences Ltd
16/11/2021ANRAnatara Lifesciences Ltd
16/11/2021 Price SensitivePSANRAnatara Lifesciences Ltd
16/11/2021 Price SensitivePSANRAnatara Lifesciences Ltd
04/11/2021ANRAnatara Lifesciences Ltd
125
MCap
29/10/2021 Price SensitivePSANRAnatara Lifesciences Ltd
27/10/2021ANRAnatara Lifesciences Ltd
21/10/2021ANRAnatara Lifesciences Ltd

Company Overview

Anatara Lifesciences Ltd is an Australia-based specialist life sciences company. The Company is focused on developing oral solutions for gastrointestinal diseases in production animals and humans. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation, which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.

ANR in the news

Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation…
Anatara Lifesciences (ANR) has received firm commitments to undertake a $1.67 million…
Anatara Lifesciences has reported on significant data for its product in treating…

Search Previous Announcements